TrialMultiple sclerosis (Houndmills, Basingstoke, England)2021

A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis.

Maria Trojano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.